Skip to main content
Premium Trial:

Request an Annual Quote

National Government Services Expands Coverage for Bio-Techne's ExoDx Prostate Cancer Test

NEW YORK – Medicare administrative contractor National Government Services has released an updated local coverage determination expanding coverage of Bio-Techne's ExoDx Prostate Test. 

Under the updated LCD, which goes into effect March 1, the contractor will cover the EPI test once per year in patients with at least one prior negative biopsy who need a repeat biopsy and are thought to be at higher risk. Patients must have moderately elevated prostate specific antigen levels, no other relative indication for prostate biopsy, and no other relative contraindication for prostate biopsy. Relative indications include a positive multiparametric MRI, a positive prior biopsy, a digital rectal exam suspicious for cancer, or other major risk factor for prostate cancer, such as a first-degree relative with prostate cancer. Relative contraindications include a life expectancy of less than 10 years, invasive treatment for benign prostatic disease, or active prostatitis on antibiotics. 

The ExoDx test joins a slate of other tests covered by the LCD for that indication, including Opko Health's 4K Score, MDxHealth's Confirm MDx, and LynxDx's MyProstate Score. 

Coverage was expanded in light of an update from the National Comprehensive Cancer Network released in January that includes the ExoDx test on the list of assays that should be considered for patients with a prior negative biopsy thought to be at higher risk for aggressive prostate cancer.

"This important coverage determination ensures that more patients will have access to noninvasive testing before moving forward with painful, risky, and potentially unnecessary biopsy procedures," Kim Kelderman, president of Bio-Techne's diagnostics and genomics segment, said in a statement.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.